Literature DB >> 20340016

Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.

Bernd Kubista1, Florian Klinglmueller, Martin Bilban, Martin Pfeiffer, Richard Lass, Alexander Giurea, Phillipp T Funovics, Cyril Toma, Martin Dominkus, Rainer Kotz, Theresia Thalhammer, Klemens Trieb, Teresa Zettl, Christian F Singer.   

Abstract

Osteosarcoma is the most common primary malignant bone tumour. Currently osteosarcoma classification is based on histological appearance. It was the aim of this study to use a more systematic approach to osteosarcoma classification based on gene expression analysis and to identify subtype specific differentially expressed genes. We analysed the global gene expression profiles of ten osteosarcoma samples using Affymetrix U133A arrays (five osteoblastic and five non-osteoblastic osteosarcoma patients). Differential gene expression analysis yielded 75 genes up-regulated and 97 genes down-regulated in osteoblastic versus non-osteoblastic osteosarcoma samples, respectively. These included genes involved in cell growth, chemotherapy resistance, angiogenesis, steroid- and neuropeptide hormone receptor activity, acute-phase response and serotonin receptor activity and members of the Wnt/ß-catenin pathway and many others. Furthermore, we validated the highly differential expression of six genes including angiopoietin 1, IGFBP3, ferredoxin 1, BMP, decorin, and fibulin 1 in osteoblastic osteosarcoma relative to non-osteoblastic osteosarcoma. Our results show the utility of gene expression analysis to study osteosarcoma subtypes, and we identified several genes that may play a role as potential therapeutic targets in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20340016      PMCID: PMC3047650          DOI: 10.1007/s00264-010-0996-6

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  39 in total

1.  Identification of drug-regulated genes in osteosarcoma cells.

Authors:  Jörg Fellenberg; Markus J Dechant; Volker Ewerbeck; Hans Mau
Journal:  Int J Cancer       Date:  2003-07-10       Impact factor: 7.396

2.  Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.

Authors:  E I Hauben; S Weeden; J Pringle; E A Van Marck; P C W Hogendoorn
Journal:  Eur J Cancer       Date:  2002-06       Impact factor: 9.162

3.  Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance.

Authors:  P D Cole; B A Kamen; R Gorlick; D Banerjee; A K Smith; E Magill; J R Bertino
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

4.  Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.

Authors:  S Ferrari; F Bertoni; M Mercuri; P Picci; S Giacomini; A Longhi; G Bacci
Journal:  Ann Oncol       Date:  2001-08       Impact factor: 32.976

5.  Decorin suppresses tumor cell-mediated angiogenesis.

Authors:  Derrick S Grant; Cigdem Yenisey; R Wesley Rose; Mason Tootell; Manoranjan Santra; Renato V Iozzo
Journal:  Oncogene       Date:  2002-07-18       Impact factor: 9.867

6.  Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma.

Authors:  E I Hauben; J Arends; J P Vandenbroucke; C J van Asperen; E Van Marck; P C W Hogendoorn
Journal:  Eur J Hum Genet       Date:  2003-08       Impact factor: 4.246

Review 7.  FGFs, their receptors, and human limb malformations: clinical and molecular correlations.

Authors:  Andrew O M Wilkie; Susannah J Patey; Shih-Hsin Kan; Ans M W van den Ouweland; Ben C J Hamel
Journal:  Am J Med Genet       Date:  2002-10-15

8.  Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome.

Authors:  Gaetano Bacci; Cristiana Forni; Stefano Ferrari; Alessandra Longhi; Franco Bertoni; Mario Mercuri; Davide Donati; Rodolfo Capanna; Gabriella Bernini; Antonio Briccoli; Elisabetta Setola; Michela Versari
Journal:  J Pediatr Hematol Oncol       Date:  2003-11       Impact factor: 1.289

9.  Identification of potential chemoresistance genes in osteosarcoma.

Authors:  Denise Katherine Walters; Patrick Steinmann; Bettina Langsam; Silvia Schmutz; Walter Born; Bruno Fuchs
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

10.  Modulation of paclitaxel resistance by annexin IV in human cancer cell lines.

Authors:  E K Han; S K Tahir; S P Cherian; N Collins; S C Ng
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

View more
  18 in total

Review 1.  The biology of small leucine-rich proteoglycans in bone pathophysiology.

Authors:  Dragana Nikitovic; John Aggelidakis; Marian F Young; Renato V Iozzo; Nikos K Karamanos; George N Tzanakakis
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

2.  Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model.

Authors:  Nino Rainusso; Tsz-Kwong Man; Ching C Lau; John Hicks; Jianhe J Shen; Alexander Yu; Lisa L Wang; Jeffrey M Rosen
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

3.  Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence?

Authors:  Philippe Hernigou; Charles Henri Flouzat Lachaniette; Jerome Delambre; Nathalie Chevallier; Helene Rouard
Journal:  Int Orthop       Date:  2014-06-07       Impact factor: 3.075

4.  Impact of close surgical margin on local recurrence and survival in osteosarcoma.

Authors:  Xin Li; Vincent M Moretti; Adedayo O Ashana; Richard D Lackman
Journal:  Int Orthop       Date:  2011-03-15       Impact factor: 3.075

5.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

6.  Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns.

Authors:  L C de Sá Rodrigues; K E Holmes; V Thompson; C M Piskun; S E Lana; M A Newton; T J Stein
Journal:  Vet Comp Oncol       Date:  2015-02-03       Impact factor: 2.613

7.  Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer.

Authors:  Liang Feng; Chan Yao; Peng Li; Ying Feng; Fei Wang; Yi-Fei Liu; Yi-Bing Guo; Qin-Sheng Mao; Wan-Jiang Xue
Journal:  Tumour Biol       Date:  2016-01-16

Review 8.  Roles of bone morphogenetic protein signaling in osteosarcoma.

Authors:  Alan Nguyen; Michelle A Scott; Sarah M Dry; Aaron W James
Journal:  Int Orthop       Date:  2014-09-11       Impact factor: 3.075

9.  Targeting the osteosarcoma cancer stem cell.

Authors:  Valerie A Siclari; Ling Qin
Journal:  J Orthop Surg Res       Date:  2010-10-27       Impact factor: 2.359

10.  The genetics of osteosarcoma.

Authors:  Jeff W Martin; Jeremy A Squire; Maria Zielenska
Journal:  Sarcoma       Date:  2012-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.